Sophiris Bio Inc (SPHS) 3.11 $SPHS
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Sophiris Bio to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Tue Mar 25, 3:05PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference. The presentation is scheduled for Tuesday, April 8th at 3:00 p.m. EDT at the Westin Grand Central Hotel in New York, New York.
Sophiris names Gerald T. Proehl to board
M2 - Fri Mar 21, 5:21AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) stated on Thursday that Gerald T. Proehl has been elected to its board of directors with effect from 19 March 2014.
Sophiris Adds Gerald T. Proehl to its Board of Directors
Business Wire - Thu Mar 20, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced the appointment of Gerald T. Proehl to its board of directors effective March 19, 2014.
Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights
Business Wire - Thu Mar 13, 3:15PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013.
Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:02AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Wednesday, March 5, 2014 at 10:40 a.m. EST at the Marriott Copley Place in Boston, Massachusetts.
Sophiris Bio to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Mon Feb 03, 3:39PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 2014 Leerink Global Healthcare Conference. The presentation is scheduled for Wednesday, February 12, 2014 at 11:05 a.m. EST at the Waldorf Astoria Hotel in New York, New York.
3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
4 Stocks Under $10 Moving Higher
at The Street - Wed Nov 20, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
Business Wire - Tue Nov 12, 3:05PM CST
Sophiris Bio Inc. (Sophiris, NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and nine months ended September 30, 2013.
Sophiris Bio to Present at the Stifel Healthcare Conference
PR Newswire - Thu Sep 05, 4:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Massachusetts. The presentation is scheduled for Thursday, September 12, 2013 at 2:05 pm ET.
Sophiris Bio Closes $65 Million Public Offering
CNW Group - Fri Aug 23, 8:38AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has closed its previously announced initial U.S. public offering (the "Offering" . The Company issued 13,000,000 common shares at a price of US$5.00 per share for aggregate gross proceeds of US$65 million.
Sophiris Bio shares slump in debut
AP - Fri Aug 16, 11:50AM CDT
NEW YORK (AP) — Shares of Sophiris Bio Inc. tumbled Friday after the drug developer slashed the price of its initial public offering while boosting the number of shares being sold.
IIROC Trade Resumption - SHS
CNW Group - Fri Aug 16, 8:51AM CDT
Trading resumes in:
IIROC Trade Resumption - Sophiris Bio Inc.
Newsfile Corp - Fri Aug 16, 8:50AM CDT
Trading resumes in:
Sophiris Bio Prices its Previously Announced Public Offering of Common Shares
CNW Group - Fri Aug 16, 8:28AM CDT
Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has entered into an underwriting agreement with Citigroup and Leerink Swann, as joint book-running managers, with respect to an offering (the "Offering" of 13,000,000 common shares of the Company (the "Shares" at a price of US$5 per Share (the "Purchase Price" for aggregate gross proceeds of approximately US$65 million. Stifel and Lazard Capital Markets are acting as co-managers. The Company has also granted to the underwriters a 30-day over-allotment option (the "Option" to purchase up to an additional 1,950,000 Shares at the Purchase Price, for additional aggregate gross proceeds of up to approximately US$9.75 million. The Company will file a final short form prospectus with the securities regulatory authorities in British Columbia and Ontario in connection with the Offering.
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Sophiris Bio to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Tue Mar 25, 3:05PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference. The presentation is scheduled for Tuesday, April 8th at 3:00 p.m. EDT at the Westin Grand Central Hotel in New York, New York. Sophiris names Gerald T. Proehl to board
M2 - Fri Mar 21, 5:21AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) stated on Thursday that Gerald T. Proehl has been elected to its board of directors with effect from 19 March 2014.
Sophiris Adds Gerald T. Proehl to its Board of Directors
Business Wire - Thu Mar 20, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced the appointment of Gerald T. Proehl to its board of directors effective March 19, 2014. Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights
Business Wire - Thu Mar 13, 3:15PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational highlights for the three months and full year ended December 31, 2013. Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:02AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Wednesday, March 5, 2014 at 10:40 a.m. EST at the Marriott Copley Place in Boston, Massachusetts. Sophiris Bio to Present at the 2014 Leerink Global Healthcare Conference
Business Wire - Mon Feb 03, 3:39PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 2014 Leerink Global Healthcare Conference. The presentation is scheduled for Wednesday, February 12, 2014 at 11:05 a.m. EST at the Waldorf Astoria Hotel in New York, New York. 3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
4 Stocks Under $10 Moving Higher
at The Street - Wed Nov 20, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
Business Wire - Tue Nov 12, 3:05PM CST
Sophiris Bio Inc. (Sophiris, NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the three and nine months ended September 30, 2013. Sophiris Bio to Present at the Stifel Healthcare Conference
PR Newswire - Thu Sep 05, 4:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that Randall E. Woods, President and Chief Executive Officer, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Massachusetts. The presentation is scheduled for Thursday, September 12, 2013 at 2:05 pm ET. Sophiris Bio Closes $65 Million Public Offering
CNW Group - Fri Aug 23, 8:38AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has closed its previously announced initial U.S. public offering (the "Offering" . The Company issued 13,000,000 common shares at a price of US$5.00 per share for aggregate gross proceeds of US$65 million. Sophiris Bio shares slump in debut
AP - Fri Aug 16, 11:50AM CDT
NEW YORK (AP) — Shares of Sophiris Bio Inc. tumbled Friday after the drug developer slashed the price of its initial public offering while boosting the number of shares being sold.
IIROC Trade Resumption - SHS
CNW Group - Fri Aug 16, 8:51AM CDT
Trading resumes in:
IIROC Trade Resumption - Sophiris Bio Inc.
Newsfile Corp - Fri Aug 16, 8:50AM CDT
Trading resumes in:
Sophiris Bio Prices its Previously Announced Public Offering of Common Shares
CNW Group - Fri Aug 16, 8:28AM CDT
Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced that it has entered into an underwriting agreement with Citigroup and Leerink Swann, as joint book-running managers, with respect to an offering (the "Offering" of 13,000,000 common shares of the Company (the "Shares" at a price of US$5 per Share (the "Purchase Price" for aggregate gross proceeds of approximately US$65 million. Stifel and Lazard Capital Markets are acting as co-managers. The Company has also granted to the underwriters a 30-day over-allotment option (the "Option" to purchase up to an additional 1,950,000 Shares at the Purchase Price, for additional aggregate gross proceeds of up to approximately US$9.75 million. The Company will file a final short form prospectus with the securities regulatory authorities in British Columbia and Ontario in connection with the Offering. 
